<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bisphosphonates (BPs) are potent inhibitors of osteoclast function, widely used to treat excessive bone resorption associated with <z:e sem="disease" ids="C0153690" disease_type="Neoplastic Process" abbrv="">bone metastases</z:e>, that also have anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="46557">Zoledronic acid</z:chebi> (<z:chebi fb="0" ids="46557">ZOL</z:chebi>) represents a potential chemotherapeutic agent for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="46557">ZOL</z:chebi> is the most potent nitrogen-containing BPs, and it inhibits cell growth and induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in a variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Recently we demonstrated that accumulation of isopentenyl <z:chebi fb="2" ids="18361">pyrophosphate</z:chebi> and the consequent formation of a new type of ATP analog (ApppI) after <z:chebi fb="0" ids="25350">mevalonate</z:chebi> pathway inhibition by nitrogen-containing BPs strongly correlates with <z:chebi fb="0" ids="46557">ZOL</z:chebi>-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in vitro </plain></SENT>
<SENT sid="4" pm="."><plain>In this study we show that <z:chebi fb="0" ids="46557">ZOL</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in HF28RA human follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells occurs exclusively via the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> pathway, involves lysosomes, and is dependent on <z:chebi fb="0" ids="25350">mevalonate</z:chebi> pathway inhibition </plain></SENT>
<SENT sid="5" pm="."><plain>To define the exact signaling pathway connecting them, we used modified HF28RA cell lines overexpressing either BclXL or dominant-negative caspase-9 </plain></SENT>
<SENT sid="6" pm="."><plain>In both mutant cells, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> and lysosomal membrane permeabilization (MMP and LMP) were totally prevented, indicating signaling between lysosomes and mitochondria and, additionally, an amplification loop for MMP and/or LMP regulated by caspase-9 in association with <z:chebi fb="0" ids="24017">farnesyl</z:chebi> <z:chebi fb="2" ids="18361">pyrophosphate</z:chebi> synthetase inhibition </plain></SENT>
<SENT sid="7" pm="."><plain>Additionally, the lysosomal pathway in <z:chebi fb="0" ids="46557">ZOL</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> plays an additional/amplification role of the intrinsic pathway independently of caspase-3 activation </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, we show a potential regulation by Bcl-XL and caspase-9 on cell cycle regulators of S-phase </plain></SENT>
<SENT sid="9" pm="."><plain>Our findings provide a molecular basis for new strategies concomitantly targeting cell <z:hpo ids='HP_0011420'>death</z:hpo> pathways from multiple sites </plain></SENT>
</text></document>